In addition with work with small molecule pharmaceuticals,
Haas and Partners brings experience with biological products and advanced therapeutics. We focus on innovative therapies in development, are highly tuned to the impact of production particularly of therapeutic proteins, and familiar with risk assessment in association with manufacturing.
- Pharmaceuticals – ADME, CYP 450, pharmacogenetics
- Biologicals – monoclonal antibodies, recombinant enzyme replacement therapies, plasma-derived products
- Advanced therapeutics – gene therapy, cell therapy, anti-sense oligonucleotides, RNAi